Browse Drug List
Drugs That Prolong the QT Interval and/or Induce Torsades de Pointes
-Raymond L. Woosley, MD, PhD
Information from the medical literature, the FDA-approved drug labeling and reports submitted to the FDA Adverse Events Reporting System database.
Browse by clicking on the first letter of the drug's brand or generic name:
A
· B
· C
· D
· E
· F
· G
· H
· I
· J
· K
· L
· M
| Generic
Name |
|
Amantadine |
PubMed Search |
| Brand
Name(s) |
|
Symmetrel® |
| Drug
Class |
|
Dopaminergic/Anti-viral |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided
for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Atomoxetine |
PubMed Search |
| Brand
Name(s) |
|
Strattera® |
| Drug
Class |
|
norepinephrine reuptake inhibitor |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Doxepin |
PubMed Search |
| Brand
Name(s) |
|
Sinequan® |
| Drug
Class |
|
Tricyclic Antidepressant |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Fluoxetine |
PubMed Search |
| Brand
Name(s) |
|
Prozac®,Sarafem® |
| Drug
Class |
|
Anti-depressant |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
| The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes. |
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Itraconazole |
PubMed Search |
| Brand
Name(s) |
|
Sporanox® |
| Drug
Class |
|
Anti-fungal |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Mesoridazine |
PubMed Search |
| Brand
Name(s) |
|
Serentil® |
| Drug
Class |
|
Anti-psychotic |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
| The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes. |
|
|
| Risk
Group |
|
A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with
diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Octreotide |
PubMed Search |
| Brand
Name(s) |
|
Sandostatin® |
| Drug
Class |
|
Endocrine |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided
for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Pseudoephedrine |
PubMed Search |
| Brand
Name(s) |
|
PediaCare®,Sudafed® |
| Drug
Class |
|
Decongestant |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Quetiapine |
PubMed Search |
| Brand
Name(s) |
|
Seroquel® |
| Drug
Class |
|
Anti-psychotic |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided
for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Salmeterol |
PubMed Search |
| Brand
Name(s) |
|
Serevent® |
| Drug
Class |
|
Sympathomimetic |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Sertindole |
PubMed Search |
| Brand
Name(s) |
|
Serdolect®,Serlect® |
| Drug
Class |
|
Antipsychotic, atypical |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided
for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Sertraline |
PubMed Search |
| Brand
Name(s) |
|
Zoloft® |
| Drug
Class |
|
Anti-depressant |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
| The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes. |
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Sibutramine |
PubMed Search |
| Brand
Name(s) |
|
Meridia® |
| Drug
Class |
|
Appetitie suppressant |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Solifenacin |
PubMed Search |
| Brand
Name(s) |
|
VESIcare® |
| Drug
Class |
|
muscarinic receptor anatagonist |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Sotalol |
PubMed Search |
| Brand
Name(s) |
|
Betapace® |
| Drug
Class |
|
Anti-arrhythmic |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
| The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes. |
|
|
| Risk
Group |
|
A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with
diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
Substantial evidence indicates a greater risk of Torsades de Pointes in women.
Females>Males |
|
|
| Generic
Name |
|
Sparfloxacin |
PubMed Search |
| Brand
Name(s) |
|
Zagam® |
| Drug
Class |
|
Antibiotic |
|
|
|
| QT |
|
| QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug. |
|
|
| TdP |
|
| The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes. |
|
|
| Risk
Group |
|
A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with
diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Sunitinib |
PubMed Search |
| Brand
Name(s) |
|
Sutent® |
| Drug
Class |
|
Anti-cancer |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided
for use in patients with diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
|
|
| Generic
Name |
|
Terfenadine |
PubMed Search |
| Brand
Name(s) |
|
Seldane® |
| Drug
Class |
|
Antihistamine |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with
diagnosed or suspected Congenital Long QT Syndrome. |
|
| Comments |
|
No longer available in U.S. |
|
|
| Generic
Name |
|
Trimethoprim-Sulfa |
PubMed Search |
| Brand
Name(s) |
|
Bactrim®,Sulfa® |
| Drug
Class |
|
Antibiotic |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
| Generic
Name |
|
Trimipramine |
PubMed Search |
| Brand
Name(s) |
|
Surmontil® |
| Drug
Class |
|
Tricyclic Antidepressant |
|
|
|
| QT |
|
|
|
| TdP |
|
|
|
| Risk
Group |
|
Drugs that carry a risk of torsades de pointes and/or QT prolongation under certain conditions, such as patients with congenital long QT syndrome, drug overdose or co-administration of interacting drugs. |
|
| Comments |
|
|
|
A note about Brand Names: Drugs are listed with up to 2 common brand names. There are many more brand names for some of the common drugs, such as pseudoephedrine and erythromycin. It is also important to look at the list of active drugs in medicines that contain a combination of drugs such as Zyrtec-D®, which contains pseudoephedrine.
